+357 96 030922
info@marketpublishers.com

Global Gastrointestinal Supply, Demand and Key Producers, 2026-2032

https://marketpublishers.com/r/GE89CA7F3BC9EN.html
Date: September 2026
Pages: 154
Price: US$ 4,480.00 (Single User License)
ID: GE89CA7F3BC9EN

Abstracts

The global Gastrointestinal market size is expected to reach $ 123509 million by 2032, rising at a market growth of 5.1% CAGR during the forecast period (2026-2032).

Gastrointestinal in this study refers to medicines used for the prevention, treatment and long-term management of diseases affecting the stomach, intestine, liver, gallbladder, pancreas and related digestive functions. The research scope covers established therapeutic categories including antacids and acid-control therapies, gastrointestinal prokinetics, antidiarrheals, laxatives, gastric mucosal protectants, digestive enzyme preparations and hepatobiliary drugs, while also reflecting the increasing role of targeted and advanced therapies in chronic gastrointestinal diseases. These products act through mechanisms such as gastric-acid suppression, mucosal protection, gastrointestinal motility regulation, stool-frequency and consistency control, digestive-enzyme supplementation, modulation of intestinal function and hepatobiliary regulation. Major clinical demand arises from gastritis, peptic ulcer, gastroesophageal reflux disease, dyspepsia, Helicobacter pylori infection, constipation, diarrhea, irritable bowel syndrome, inflammatory bowel disease and selected hepatobiliary disorders. The Gastrointestinal market therefore combines large-volume mature therapies with higher-value innovative medicines, creating a diversified pharmaceutical market characterized by substantial differences in treatment duration, clinical complexity, pricing and commercialization models.

Key Findings

Mature therapies maintain scale but face sustained pricing pressure

+357 96 030922
info@marketpublishers.com

P-CAB adoption is upgrading the acid-control treatment segment

IBD value growth is shifting toward targeted advanced therapies

China offers substantial structural upgrade opportunities in chronic gastrointestinal care

Market Trends

The Gastrointestinal market is moving from a predominantly symptom-control model toward a more differentiated structure combining conventional high-volume medicines with mechanism-based and disease-modifying therapies. Mature categories such as conventional acid-control drugs, antidiarrheals, laxatives, prokinetics and mucosal protectants remain important because of their broad patient base and recurring demand, but their commercial value is increasingly constrained by generic competition and pricing pressure. At the innovation end, P-CAB therapies are expanding treatment options in acid-related diseases, while chronic inflammatory gastrointestinal diseases are increasingly treated with biologics and targeted small molecules, including IL-23 and JAK pathway therapies. Regulatory expansion of P-CAB indications across erosive and non-erosive GERD and continued development of targeted therapies in Crohn's disease and ulcerative colitis reinforce this structural transition. The long-term direction of the market is therefore not simply greater medicine consumption, but an increase in treatment precision, durability of disease control, convenient administration and lifecycle management.

Market Dynamics

Drivers

Demand for Gastrointestinal medicines is supported by the unusually broad patient base across acute, recurrent and chronic digestive diseases. Acid-related disorders, functional gastrointestinal conditions, constipation and diarrhea generate large recurring treatment volumes, while chronic conditions such as inflammatory bowel disease require longer treatment duration and continuous disease management. Greater diagnosis and treatment standardization are also increasing the proportion of patients receiving sustained pharmaceutical intervention rather than episodic symptom relief. At the same time, new mechanisms and improved formulations are extending treatment

+357 96 030922
info@marketpublishers.com

options in areas where conventional medicines provide incomplete response. The continued commercial importance of gastroenterology portfolios at major pharmaceutical companies, together with ongoing expansion of therapies for ulcerative colitis, Crohn's disease and other chronic gastrointestinal conditions, confirms that long-term treatment demand has become an increasingly important value driver for the Gastrointestinal market.

Restraints

The principal restraint on the Gastrointestinal market is the widening economic gap between mature and innovative therapies. Many traditional gastrointestinal medicines have well-established mechanisms, numerous generic alternatives and relatively low barriers to therapeutic substitution, resulting in sustained price competition and limited room for premium pricing. In innovative segments, development costs, clinical-trial requirements and regulatory standards are substantially higher, while reimbursement decisions increasingly depend on demonstrated clinical differentiation and long-term outcomes. Gastrointestinal diseases are also highly heterogeneous, and treatment response may vary according to disease severity, phenotype, previous therapies and patient characteristics. As a result, a clinically successful product does not automatically translate into rapid commercial penetration. Safety monitoring and long-term risk-benefit assessment are particularly important for systemic advanced therapies, increasing the evidence burden required to support broader treatment adoption.

Opportunities

The most attractive opportunities are concentrated in structural substitution rather than simple expansion of established drug volumes. In acid-related disease, P-CAB technology creates opportunities to upgrade treatment pathways in GERD and H. pylori-related therapy and to capture value from patients with persistent or recurrent symptoms. In chronic gastrointestinal disease, biologics and targeted oral therapies provide additional opportunities through earlier-line use, additional indications, optimized administration and improved long-term disease control. China represents another important structural opportunity as standardized diagnosis, H. pylori management, access to targeted IBD medicines and biosimilar development gradually reshape the treatment mix. At the same time, functional disorders such as irritable bowel syndrome and chronic constipation continue to present unmet needs because treatment outcomes remain variable and patients frequently cycle through different therapeutic approaches. These areas provide room for differentiated mechanisms,

+357 96 030922
info@marketpublishers.com

improved adherence and more precise patient selection.

Challenges

The Gastrointestinal market faces a dual commercialization challenge. Mature medicines must compete primarily through manufacturing efficiency, price, product quality and broad distribution, while innovative medicines require stronger clinical differentiation, physician adoption, reimbursement access and lifecycle management. This creates very different success factors within the same overall market. For innovative therapies, increasingly crowded treatment pathways can raise the threshold for demonstrating incremental clinical value, particularly as multiple biologic and targeted mechanisms become available for the same chronic gastrointestinal indication. Companies must also balance expansion of treatment duration and indications against long-term safety requirements and affordability constraints. In emerging markets, improving access may increase patient penetration but can simultaneously intensify price competition. Consequently, sustainable growth depends increasingly on the ability to demonstrate clinically meaningful differentiation while maintaining economically acceptable treatment costs.

Industry Chain Analysis

The Gastrointestinal industry chain begins with pharmaceutical APIs, intermediates, excipients, formulation materials and, for biologic products, cell-culture materials and specialized bioprocessing inputs. Midstream value creation includes drug discovery, formulation development, clinical development, regulatory registration, manufacturing, quality control and lifecycle management. Manufacturing economics differ substantially across product categories. Mature oral gastrointestinal drugs generally have standardized production processes and relatively high competitive exposure to API costs, manufacturing efficiency and scale, whereas innovative biologics and targeted therapies place greater value on intellectual property, clinical evidence, complex manufacturing capability and regulatory expertise. Downstream commercialization is conducted mainly through hospitals, retail pharmacies and specialized pharmaceutical distribution channels, with the relative importance of each channel varying by disease severity and treatment complexity. Conventional symptom-relief products depend heavily on broad distribution and availability, while advanced therapies rely more strongly on specialist physicians, diagnosis pathways, reimbursement access and patient-management capabilities. Consequently, the value pool is gradually shifting from

+357 96 030922
info@marketpublishers.com

manufacturing-centered mature products toward R&D, clinical evidence and differentiated therapeutic outcomes.

Segment Insights

Within the established Gastrointestinal classification, antacids and acid-control medicines, gastrointestinal prokinetics, antidiarrheals, laxatives, gastric mucosal protectants, digestive enzymes and hepatobiliary drugs continue to form the broad foundation of market demand. These categories benefit from large patient populations and frequent use, but many are mature and therefore face stronger generic competition and price sensitivity. Their strategic importance lies more in stable volume, brand recognition and channel coverage than in rapid value expansion. In contrast, the higher-value portion of the market is increasingly associated with technological and therapeutic upgrades. P-CAB products represent an important innovation within acid-control treatment, while targeted therapies are reshaping chronic inflammatory gastrointestinal disease management. The resulting market structure is increasingly polarized: mature products provide demand stability and commercial scale, whereas innovative therapies contribute disproportionately to incremental value creation. This divergence is expected to remain a defining characteristic of the Gastrointestinal market.

Downstream Market Opportunities

Downstream demand spans both common digestive symptoms and diseases requiring prolonged specialist management. Gastritis, peptic ulcer, dyspepsia, GERD, constipation and diarrhea provide a broad base of recurring pharmaceutical demand, while H. pylori infection creates opportunities linked to standardized eradication therapy and acid-control optimization. Chronic diseases such as inflammatory bowel disease have a different commercial profile because treatment may extend for years and therapeutic switching, maintenance treatment and monitoring become important components of patient management. Functional disorders such as irritable bowel syndrome and chronic constipation also remain commercially relevant because symptom recurrence and heterogeneous treatment response can lead to repeated use of multiple drug classes. Downstream opportunities are therefore shifting from simply increasing patient numbers toward improving diagnosis, extending effective treatment duration, increasing adherence and moving appropriate patients toward more differentiated therapies.

+357 96 030922
info@marketpublishers.com

Regional Insights

The Gastrointestinal market displays a clear regional difference between pharmaceutical value and treatment volume. North America and Western Europe represent high-value markets for innovative gastrointestinal therapies because specialist treatment pathways, advanced biologics and targeted medicines have comparatively strong penetration, while mature gastrointestinal medicines remain highly competitive. Continued investment by major pharmaceutical companies in Crohn's disease and ulcerative colitis illustrates the commercial importance of advanced gastrointestinal treatment in developed markets. Asia represents a structurally important market because of its large patient population and the coexistence of substantial conventional-drug demand with increasing adoption of innovative therapies. China is particularly relevant to future market restructuring: opportunities are increasingly linked to treatment standardization, improved diagnosis of chronic gastrointestinal disease, wider access to targeted medicines, localization and biosimilar competition. Regional growth potential therefore depends not only on patient numbers, but also on the speed at which treatment pathways shift from basic symptom management toward standardized and higher-value chronic disease management.

Report Scope

This report studies the global Gastrointestinal demand, key companies, and key regions.

This report is a detailed and comprehensive analysis of the world market for Gastrointestinal, and provides market size (US$ million) and Year-over-Year (YoY) growth, considering 2025 as the base year. This report explores demand trends and competition, as well as details the characteristics of Gastrointestinal that contribute to its increasing demand across many markets.

Highlights and key features of the study

Global Gastrointestinal total market, 2021-2032, (USD Million)

Global Gastrointestinal total market by region & country, CAGR, 2021-2032, (USD Million)

+357 96 030922
info@marketpublishers.com

U.S. VS China: Gastrointestinal total market, key domestic companies, and share, (USD Million)

Global Gastrointestinal revenue by player, revenue and market share 2021-2026, (USD Million)

Global Gastrointestinal total market by Type, CAGR, 2021-2032, (USD Million)

Global Gastrointestinal total market by Application, CAGR, 2021-2032, (USD Million)

This report profiles major players in the global Gastrointestinal market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include AstraZeneca, Sanofi, Bayer, Pfizer, GlaxoSmithKline, Teva, Ferring Pharmaceuticals, Perrigo, Boehringer Ingelheim, Purdue Pharma, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the world Gastrointestinal market

Detailed Segmentation:

Each section contains quantitative market data including market by value (US$ Millions), by player, by regions, by Type, and by Application. Data is given for the years 2021-2032 by year with 2025 as the base year, 2026 as the estimate year, and 2027-2032 as the forecast year.

Global Gastrointestinal Market, By Region:

United States

China

+357 96 030922
info@marketpublishers.com

Europe

Japan

South Korea

ASEAN

India

Rest of World

Market Segmentation

Global Gastrointestinal Market, Segmentation by Type:

Acid-Related Disorder Drugs

Inflammatory Bowel Disease Drugs

Irritable Bowel Syndrome Drugs

Constipation Drugs

Diarrhea Drugs

Gastrointestinal Motility Disorder Drugs

Other Gastrointestinal Drugs

Global Gastrointestinal Market, Segmentation by Primary Dosage Form:

Oral Solid Preparations

Oral Liquid and Suspension Preparations

+357 96 030922
info@marketpublishers.com

Injectable Preparations

Rectal Preparations

Other Preparations

Global Gastrointestinal Market, Segmentation by Drug Molecule:

Small Molecule Drugs

Biologic Drugs

Global Gastrointestinal Market, Segmentation by Application:

Hospitals

Gastroenterology Clinics

Retail Pharmacies

Online Pharmacies

Companies Profiled:

AstraZeneca

Sanofi

Bayer

Pfizer

GlaxoSmithKline

+357 96 030922
info@marketpublishers.com

Teva

Ferring Pharmaceuticals

Perrigo

Boehringer Ingelheim

Purdue Pharma

Dr. Falk Pharma GmbH

Abbott

Jiangzhong

Xian-Janssen

Takeda Pharmaceutical

AbbVie

Eli Lilly and Company

Johnson & Johnson

Bristol Myers Squibb

Bausch Health

Livzon Pharmaceutical

Shandong Luoxin Pharmaceutical

Gilead Sciences

Zhengdatianqing

Zydus Lifesciences

+357 96 030922
info@marketpublishers.com

Key Questions Answered

1. How big is the global Gastrointestinal market?
2. What is the demand of the global Gastrointestinal market?
3. What is the year over year growth of the global Gastrointestinal market?
4. What is the total value of the global Gastrointestinal market?
5. Who are the Major Players in the global Gastrointestinal market?
6. What are the growth factors driving the market demand?

+357 96 030922
info@marketpublishers.com

Contents

1 SUPPLY SUMMARY

1.1 Gastrointestinal Introduction
1.2 World Gastrointestinal Market Size & Forecast (2021 & 2025 & 2032)
1.3 World Gastrointestinal Total Market by Region (by Headquarter Location)
  1.3.1 World Gastrointestinal Market Size by Region (2021-2032), (by Headquarter Location)
  1.3.2 United States Based Company Gastrointestinal Revenue (2021-2032)
  1.3.3 China Based Company Gastrointestinal Revenue (2021-2032)
  1.3.4 Europe Based Company Gastrointestinal Revenue (2021-2032)
  1.3.5 Japan Based Company Gastrointestinal Revenue (2021-2032)
  1.3.6 South Korea Based Company Gastrointestinal Revenue (2021-2032)
  1.3.7 ASEAN Based Company Gastrointestinal Revenue (2021-2032)
  1.3.8 India Based Company Gastrointestinal Revenue (2021-2032)
1.4 Market Drivers, Restraints and Trends
  1.4.1 Gastrointestinal Market Drivers
  1.4.2 Factors Affecting Demand
  1.4.3 Major Market Trends

2 DEMAND SUMMARY

2.1 World Gastrointestinal Consumption Value (2021-2032)
2.2 World Gastrointestinal Consumption Value by Region
  2.2.1 World Gastrointestinal Consumption Value by Region (2021-2026)
  2.2.2 World Gastrointestinal Consumption Value Forecast by Region (2027-2032)
2.3 United States Gastrointestinal Consumption Value (2021-2032)
2.4 China Gastrointestinal Consumption Value (2021-2032)
2.5 Europe Gastrointestinal Consumption Value (2021-2032)
2.6 Japan Gastrointestinal Consumption Value (2021-2032)
2.7 South Korea Gastrointestinal Consumption Value (2021-2032)
2.8 ASEAN Gastrointestinal Consumption Value (2021-2032)
2.9 India Gastrointestinal Consumption Value (2021-2032)

3 WORLD GASTROINTESTINAL COMPANIES COMPETITIVE ANALYSIS

3.1 World Gastrointestinal Revenue by Player (2021-2026)
3.2 Industry Rank and Concentration Rate (CR)

+357 96 030922
info@marketpublishers.com

3.2.1 Global Gastrointestinal Industry Rank of Major Players
3.2.2 Global Concentration Ratios (CR4) for Gastrointestinal in 2025
3.2.3 Global Concentration Ratios (CR8) for Gastrointestinal in 2025
3.3 Gastrointestinal Company Evaluation Quadrant
3.4 Gastrointestinal Market: Overall Company Footprint Analysis
3.4.1 Gastrointestinal Market: Region Footprint
3.4.2 Gastrointestinal Market: Company Product Type Footprint
3.4.3 Gastrointestinal Market: Company Product Application Footprint
3.5 Competitive Environment
3.5.1 Historical Structure of the Industry
3.5.2 Barriers of Market Entry
3.5.3 Factors of Competition
3.6 Mergers & Acquisitions Activity

4 UNITED STATES VS CHINA VS REST OF WORLD (BY HEADQUARTER LOCATION)

4.1 United States VS China: Gastrointestinal Revenue Comparison (by Headquarter Location)
4.1.1 United States VS China: Gastrointestinal Revenue Comparison (2021 & 2025 & 2032) (by Headquarter Location)
4.1.2 United States VS China: Gastrointestinal Revenue Market Share Comparison (2021 & 2025 & 2032)
4.2 United States Based Companies VS China Based Companies: Gastrointestinal Consumption Value Comparison
4.2.1 United States VS China: Gastrointestinal Consumption Value Comparison (2021 & 2025 & 2032)
4.2.2 United States VS China: Gastrointestinal Consumption Value Market Share Comparison (2021 & 2025 & 2032)
4.3 United States Based Gastrointestinal Companies and Market Share, 2021-2026
4.3.1 United States Based Gastrointestinal Companies, Headquarters (States, Country)
4.3.2 United States Based Companies Gastrointestinal Revenue, (2021-2026)
4.4 China Based Companies Gastrointestinal Revenue and Market Share, 2021-2026
4.4.1 China Based Gastrointestinal Companies, Company Headquarters (Province, Country)
4.4.2 China Based Companies Gastrointestinal Revenue, (2021-2026)
4.5 Rest of World Based Gastrointestinal Companies and Market Share, 2021-2026
4.5.1 Rest of World Based Gastrointestinal Companies, Headquarters (Province,

+357 96 030922
info@marketpublishers.com

Country)
4.5.2 Rest of World Based Companies Gastrointestinal Revenue (2021-2026)

5 MARKET ANALYSIS BY TYPE

5.1 World Gastrointestinal Market Size Overview by Type: 2021 VS 2025 VS 2032
5.2 Segment Introduction by Type
5.2.1 Acid-Related Disorder Drugs
5.2.2 Inflammatory Bowel Disease Drugs
5.2.3 Irritable Bowel Syndrome Drugs
5.2.4 Constipation Drugs
5.2.5 Diarrhea Drugs
5.2.6 Gastrointestinal Motility Disorder Drugs
5.2.7 Other Gastrointestinal Drugs
5.3 Market Segment by Type
5.3.1 World Gastrointestinal Market Size by Type (2021-2026)
5.3.2 World Gastrointestinal Market Size by Type (2027-2032)
5.3.3 World Gastrointestinal Market Size Market Share by Type (2027-2032)

6 MARKET ANALYSIS BY PRIMARY DOSAGE FORM

6.1 World Gastrointestinal Market Size Overview by Primary Dosage Form: 2021 VS 2025 VS 2032
6.2 Segment Introduction by Primary Dosage Form
6.2.1 Oral Solid Preparations
6.2.2 Oral Liquid and Suspension Preparations
6.2.3 Injectable Preparations
6.2.4 Rectal Preparations
6.2.5 Other Preparations
6.3 Market Segment by Primary Dosage Form
6.3.1 World Gastrointestinal Market Size by Primary Dosage Form (2021-2026)
6.3.2 World Gastrointestinal Market Size by Primary Dosage Form (2027-2032)
6.3.3 World Gastrointestinal Market Size Market Share by Primary Dosage Form (2027-2032)

7 MARKET ANALYSIS BY DRUG MOLECULE

7.1 World Gastrointestinal Market Size Overview by Drug Molecule: 2021 VS 2025 VS 2032

+357 96 030922
info@marketpublishers.com

7.2 Segment Introduction by Drug Molecule
7.2.1 Small Molecule Drugs
7.2.2 Biologic Drugs
7.3 Market Segment by Drug Molecule
7.3.1 World Gastrointestinal Market Size by Drug Molecule (2021-2026)
7.3.2 World Gastrointestinal Market Size by Drug Molecule (2027-2032)
7.3.3 World Gastrointestinal Market Size Market Share by Drug Molecule (2027-2032)

8 MARKET ANALYSIS BY APPLICATION

8.1 World Gastrointestinal Market Size Overview by Application: 2021 VS 2025 VS 2032
8.2 Segment Introduction by Application
8.2.1 Hospitals
8.2.2 Gastroenterology Clinics
8.2.3 Retail Pharmacies
8.2.4 Online Pharmacies
8.3 Market Segment by Application
8.3.1 World Gastrointestinal Market Size by Application (2021-2026)
8.3.2 World Gastrointestinal Market Size by Application (2027-2032)
8.3.3 World Gastrointestinal Market Size Market Share by Application (2021-2032)

9 COMPANY PROFILES

9.1 AstraZeneca
9.1.1 AstraZeneca Details
9.1.2 AstraZeneca Major Business
9.1.3 AstraZeneca Gastrointestinal Product and Services
9.1.4 AstraZeneca Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.1.5 AstraZeneca Recent Developments/Updates
9.1.6 AstraZeneca Competitive Strengths & Weaknesses
9.2 Sanofi
9.2.1 Sanofi Details
9.2.2 Sanofi Major Business
9.2.3 Sanofi Gastrointestinal Product and Services
9.2.4 Sanofi Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.2.5 Sanofi Recent Developments/Updates
9.2.6 Sanofi Competitive Strengths & Weaknesses

+357 96 030922
info@marketpublishers.com

9.3 Bayer
9.3.1 Bayer Details
9.3.2 Bayer Major Business
9.3.3 Bayer Gastrointestinal Product and Services
9.3.4 Bayer Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.3.5 Bayer Recent Developments/Updates
9.3.6 Bayer Competitive Strengths & Weaknesses
9.4 Pfizer
9.4.1 Pfizer Details
9.4.2 Pfizer Major Business
9.4.3 Pfizer Gastrointestinal Product and Services
9.4.4 Pfizer Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.4.5 Pfizer Recent Developments/Updates
9.4.6 Pfizer Competitive Strengths & Weaknesses
9.5 GlaxoSmithKline
9.5.1 GlaxoSmithKline Details
9.5.2 GlaxoSmithKline Major Business
9.5.3 GlaxoSmithKline Gastrointestinal Product and Services
9.5.4 GlaxoSmithKline Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.5.5 GlaxoSmithKline Recent Developments/Updates
9.5.6 GlaxoSmithKline Competitive Strengths & Weaknesses
9.6 Teva
9.6.1 Teva Details
9.6.2 Teva Major Business
9.6.3 Teva Gastrointestinal Product and Services
9.6.4 Teva Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.6.5 Teva Recent Developments/Updates
9.6.6 Teva Competitive Strengths & Weaknesses
9.7 Ferring Pharmaceuticals
9.7.1 Ferring Pharmaceuticals Details
9.7.2 Ferring Pharmaceuticals Major Business
9.7.3 Ferring Pharmaceuticals Gastrointestinal Product and Services
9.7.4 Ferring Pharmaceuticals Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.7.5 Ferring Pharmaceuticals Recent Developments/Updates
9.7.6 Ferring Pharmaceuticals Competitive Strengths & Weaknesses
9.8 Perrigo
9.8.1 Perrigo Details

+357 96 030922
info@marketpublishers.com

9.8.2 Perrigo Major Business
9.8.3 Perrigo Gastrointestinal Product and Services
9.8.4 Perrigo Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.8.5 Perrigo Recent Developments/Updates
9.8.6 Perrigo Competitive Strengths & Weaknesses
9.9 Boehringer Ingelheim
9.9.1 Boehringer Ingelheim Details
9.9.2 Boehringer Ingelheim Major Business
9.9.3 Boehringer Ingelheim Gastrointestinal Product and Services
9.9.4 Boehringer Ingelheim Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.9.5 Boehringer Ingelheim Recent Developments/Updates
9.9.6 Boehringer Ingelheim Competitive Strengths & Weaknesses
9.10 Purdue Pharma
9.10.1 Purdue Pharma Details
9.10.2 Purdue Pharma Major Business
9.10.3 Purdue Pharma Gastrointestinal Product and Services
9.10.4 Purdue Pharma Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.10.5 Purdue Pharma Recent Developments/Updates
9.10.6 Purdue Pharma Competitive Strengths & Weaknesses
9.11 Dr. Falk Pharma GmbH
9.11.1 Dr. Falk Pharma GmbH Details
9.11.2 Dr. Falk Pharma GmbH Major Business
9.11.3 Dr. Falk Pharma GmbH Gastrointestinal Product and Services
9.11.4 Dr. Falk Pharma GmbH Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.11.5 Dr. Falk Pharma GmbH Recent Developments/Updates
9.11.6 Dr. Falk Pharma GmbH Competitive Strengths & Weaknesses
9.12 Abbott
9.12.1 Abbott Details
9.12.2 Abbott Major Business
9.12.3 Abbott Gastrointestinal Product and Services
9.12.4 Abbott Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.12.5 Abbott Recent Developments/Updates
9.12.6 Abbott Competitive Strengths & Weaknesses
9.13 Jiangzhong
9.13.1 Jiangzhong Details
9.13.2 Jiangzhong Major Business

+357 96 030922
info@marketpublishers.com

9.13.3 Jiangzhong Gastrointestinal Product and Services
9.13.4 Jiangzhong Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.13.5 Jiangzhong Recent Developments/Updates
9.13.6 Jiangzhong Competitive Strengths & Weaknesses
9.14 Xian-Janssen
9.14.1 Xian-Janssen Details
9.14.2 Xian-Janssen Major Business
9.14.3 Xian-Janssen Gastrointestinal Product and Services
9.14.4 Xian-Janssen Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.14.5 Xian-Janssen Recent Developments/Updates
9.14.6 Xian-Janssen Competitive Strengths & Weaknesses
9.15 Takeda Pharmaceutical
9.15.1 Takeda Pharmaceutical Details
9.15.2 Takeda Pharmaceutical Major Business
9.15.3 Takeda Pharmaceutical Gastrointestinal Product and Services
9.15.4 Takeda Pharmaceutical Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.15.5 Takeda Pharmaceutical Recent Developments/Updates
9.15.6 Takeda Pharmaceutical Competitive Strengths & Weaknesses
9.16 AbbVie
9.16.1 AbbVie Details
9.16.2 AbbVie Major Business
9.16.3 AbbVie Gastrointestinal Product and Services
9.16.4 AbbVie Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.16.5 AbbVie Recent Developments/Updates
9.16.6 AbbVie Competitive Strengths & Weaknesses
9.17 Eli Lilly and Company
9.17.1 Eli Lilly and Company Details
9.17.2 Eli Lilly and Company Major Business
9.17.3 Eli Lilly and Company Gastrointestinal Product and Services
9.17.4 Eli Lilly and Company Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.17.5 Eli Lilly and Company Recent Developments/Updates
9.17.6 Eli Lilly and Company Competitive Strengths & Weaknesses
9.18 Johnson & Johnson
9.18.1 Johnson & Johnson Details
9.18.2 Johnson & Johnson Major Business

+357 96 030922
info@marketpublishers.com

9.18.3 Johnson & Johnson Gastrointestinal Product and Services
9.18.4 Johnson & Johnson Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.18.5 Johnson & Johnson Recent Developments/Updates
9.18.6 Johnson & Johnson Competitive Strengths & Weaknesses
9.19 Bristol Myers Squibb
9.19.1 Bristol Myers Squibb Details
9.19.2 Bristol Myers Squibb Major Business
9.19.3 Bristol Myers Squibb Gastrointestinal Product and Services
9.19.4 Bristol Myers Squibb Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.19.5 Bristol Myers Squibb Recent Developments/Updates
9.19.6 Bristol Myers Squibb Competitive Strengths & Weaknesses
9.20 Bausch Health
9.20.1 Bausch Health Details
9.20.2 Bausch Health Major Business
9.20.3 Bausch Health Gastrointestinal Product and Services
9.20.4 Bausch Health Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.20.5 Bausch Health Recent Developments/Updates
9.20.6 Bausch Health Competitive Strengths & Weaknesses
9.21 Livzon Pharmaceutical
9.21.1 Livzon Pharmaceutical Details
9.21.2 Livzon Pharmaceutical Major Business
9.21.3 Livzon Pharmaceutical Gastrointestinal Product and Services
9.21.4 Livzon Pharmaceutical Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.21.5 Livzon Pharmaceutical Recent Developments/Updates
9.21.6 Livzon Pharmaceutical Competitive Strengths & Weaknesses
9.22 Shandong Luoxin Pharmaceutical
9.22.1 Shandong Luoxin Pharmaceutical Details
9.22.2 Shandong Luoxin Pharmaceutical Major Business
9.22.3 Shandong Luoxin Pharmaceutical Gastrointestinal Product and Services
9.22.4 Shandong Luoxin Pharmaceutical Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.22.5 Shandong Luoxin Pharmaceutical Recent Developments/Updates
9.22.6 Shandong Luoxin Pharmaceutical Competitive Strengths & Weaknesses
9.23 Gilead Sciences
9.23.1 Gilead Sciences Details

+357 96 030922
info@marketpublishers.com

9.23.2 Gilead Sciences Major Business
9.23.3 Gilead Sciences Gastrointestinal Product and Services
9.23.4 Gilead Sciences Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.23.5 Gilead Sciences Recent Developments/Updates
9.23.6 Gilead Sciences Competitive Strengths & Weaknesses
9.24 Zhengdatianqing
9.24.1 Zhengdatianqing Details
9.24.2 Zhengdatianqing Major Business
9.24.3 Zhengdatianqing Gastrointestinal Product and Services
9.24.4 Zhengdatianqing Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.24.5 Zhengdatianqing Recent Developments/Updates
9.24.6 Zhengdatianqing Competitive Strengths & Weaknesses
9.25 Zydus Lifesciences
9.25.1 Zydus Lifesciences Details
9.25.2 Zydus Lifesciences Major Business
9.25.3 Zydus Lifesciences Gastrointestinal Product and Services
9.25.4 Zydus Lifesciences Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026)
9.25.5 Zydus Lifesciences Recent Developments/Updates
9.25.6 Zydus Lifesciences Competitive Strengths & Weaknesses

10 INDUSTRY CHAIN ANALYSIS

10.1 Gastrointestinal Industry Chain
10.2 Gastrointestinal Upstream Analysis
10.3 Gastrointestinal Midstream Analysis
10.4 Gastrointestinal Downstream Analysis

11 RESEARCH FINDINGS AND CONCLUSION

12 APPENDIX

12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer

+357 96 030922
info@marketpublishers.com

List Of Tables

LIST OF TABLES

Table 1. World Gastrointestinal Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Table 2. World Gastrointestinal Revenue by Region (2021-2026) & (USD Million), (by Headquarter Location)
Table 3. World Gastrointestinal Revenue by Region (2027-2032) & (USD Million), (by Headquarter Location)
Table 4. World Gastrointestinal Revenue Market Share by Region (2021-2026), (by Headquarter Location)
Table 5. World Gastrointestinal Revenue Market Share by Region (2027-2032), (by Headquarter Location)
Table 6. Major Market Trends
Table 7. World Gastrointestinal Consumption Value Growth Rate Forecast by Region (2021 & 2025 & 2032) & (USD Million)
Table 8. World Gastrointestinal Consumption Value by Region (2021-2026) & (USD Million)
Table 9. World Gastrointestinal Consumption Value Forecast by Region (2027-2032) & (USD Million)
Table 10. World Gastrointestinal Revenue by Player (2021-2026) & (USD Million)
Table 11. Revenue Market Share of Key Gastrointestinal Players in 2025
Table 12. World Gastrointestinal Industry Rank of Major Player, Based on Revenue in 2025
Table 13. Global Gastrointestinal Company Evaluation Quadrant
Table 14. Head Office of Key Gastrointestinal Players
Table 15. Gastrointestinal Market: Company Product Type Footprint
Table 16. Gastrointestinal Market: Company Product Application Footprint
Table 17. Gastrointestinal Mergers & Acquisitions Activity
Table 18. United States VS China Gastrointestinal Revenue Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 19. United States VS China Gastrointestinal Consumption Value Comparison, (2021 & 2025 & 2032) & (USD Million)
Table 20. United States Based Gastrointestinal Companies, Headquarters (States, Country)
Table 21. United States Based Companies Gastrointestinal Revenue, (2021-2026) & (USD Million)
Table 22. United States Based Companies Gastrointestinal Revenue Market Share

+357 96 030922
info@marketpublishers.com

(2021-2026)
Table 23. China Based Gastrointestinal Companies, Headquarters (Province, Country)
Table 24. China Based Companies Gastrointestinal Revenue, (2021-2026) & (USD Million)
Table 25. China Based Companies Gastrointestinal Revenue Market Share (2021-2026)
Table 26. Rest of World Based Gastrointestinal Companies, Headquarters (Province, Country)
Table 27. Rest of World Based Companies Gastrointestinal Revenue (2021-2026) & (USD Million)
Table 28. Rest of World Based Companies Gastrointestinal Revenue Market Share (2021-2026)
Table 29. World Gastrointestinal Market Size by Type, (USD Million), 2021 & 2025 & 2032
Table 30. World Gastrointestinal Market Size Value by Type (2021-2026) & (USD Million)
Table 31. World Gastrointestinal Market Size by Type (2027-2032) & (USD Million)
Table 32. World Gastrointestinal Market Size by Primary Dosage Form, (USD Million), 2021 & 2025 & 2032
Table 33. World Gastrointestinal Market Size Value by Primary Dosage Form (2021-2026) & (USD Million)
Table 34. World Gastrointestinal Market Size by Primary Dosage Form (2027-2032) & (USD Million)
Table 35. World Gastrointestinal Market Size by Drug Molecule, (USD Million), 2021 & 2025 & 2032
Table 36. World Gastrointestinal Market Size Value by Drug Molecule (2021-2026) & (USD Million)
Table 37. World Gastrointestinal Market Size by Drug Molecule (2027-2032) & (USD Million)
Table 38. World Gastrointestinal Market Size by Application, (USD Million), 2021 & 2025 & 2032
Table 39. World Gastrointestinal Market Size by Application (2021-2026) & (USD Million)
Table 40. World Gastrointestinal Market Size by Application (2027-2032) & (USD Million)
Table 41. AstraZeneca Basic Information, Manufacturing Base and Competitors
Table 42. AstraZeneca Major Business
Table 43. AstraZeneca Gastrointestinal Product and Services
Table 44. AstraZeneca Gastrointestinal Revenue, Gross Margin and Market Share

+357 96 030922
info@marketpublishers.com

(2021-2026) & (USD Million)
Table 45. AstraZeneca Recent Developments/Updates
Table 46. AstraZeneca Competitive Strengths & Weaknesses
Table 47. Sanofi Basic Information, Manufacturing Base and Competitors
Table 48. Sanofi Major Business
Table 49. Sanofi Gastrointestinal Product and Services
Table 50. Sanofi Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 51. Sanofi Recent Developments/Updates
Table 52. Sanofi Competitive Strengths & Weaknesses
Table 53. Bayer Basic Information, Manufacturing Base and Competitors
Table 54. Bayer Major Business
Table 55. Bayer Gastrointestinal Product and Services
Table 56. Bayer Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 57. Bayer Recent Developments/Updates
Table 58. Bayer Competitive Strengths & Weaknesses
Table 59. Pfizer Basic Information, Manufacturing Base and Competitors
Table 60. Pfizer Major Business
Table 61. Pfizer Gastrointestinal Product and Services
Table 62. Pfizer Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 63. Pfizer Recent Developments/Updates
Table 64. Pfizer Competitive Strengths & Weaknesses
Table 65. GlaxoSmithKline Basic Information, Manufacturing Base and Competitors
Table 66. GlaxoSmithKline Major Business
Table 67. GlaxoSmithKline Gastrointestinal Product and Services
Table 68. GlaxoSmithKline Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 69. GlaxoSmithKline Recent Developments/Updates
Table 70. GlaxoSmithKline Competitive Strengths & Weaknesses
Table 71. Teva Basic Information, Manufacturing Base and Competitors
Table 72. Teva Major Business
Table 73. Teva Gastrointestinal Product and Services
Table 74. Teva Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 75. Teva Recent Developments/Updates
Table 76. Teva Competitive Strengths & Weaknesses
Table 77. Ferring Pharmaceuticals Basic Information, Manufacturing Base and

+357 96 030922
info@marketpublishers.com

Competitors
Table 78. Ferring Pharmaceuticals Major Business
Table 79. Ferring Pharmaceuticals Gastrointestinal Product and Services
Table 80. Ferring Pharmaceuticals Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 81. Ferring Pharmaceuticals Recent Developments/Updates
Table 82. Ferring Pharmaceuticals Competitive Strengths & Weaknesses
Table 83. Perrigo Basic Information, Manufacturing Base and Competitors
Table 84. Perrigo Major Business
Table 85. Perrigo Gastrointestinal Product and Services
Table 86. Perrigo Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 87. Perrigo Recent Developments/Updates
Table 88. Perrigo Competitive Strengths & Weaknesses
Table 89. Boehringer Ingelheim Basic Information, Manufacturing Base and Competitors
Table 90. Boehringer Ingelheim Major Business
Table 91. Boehringer Ingelheim Gastrointestinal Product and Services
Table 92. Boehringer Ingelheim Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 93. Boehringer Ingelheim Recent Developments/Updates
Table 94. Boehringer Ingelheim Competitive Strengths & Weaknesses
Table 95. Purdue Pharma Basic Information, Manufacturing Base and Competitors
Table 96. Purdue Pharma Major Business
Table 97. Purdue Pharma Gastrointestinal Product and Services
Table 98. Purdue Pharma Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 99. Purdue Pharma Recent Developments/Updates
Table 100. Purdue Pharma Competitive Strengths & Weaknesses
Table 101. Dr. Falk Pharma GmbH Basic Information, Manufacturing Base and Competitors
Table 102. Dr. Falk Pharma GmbH Major Business
Table 103. Dr. Falk Pharma GmbH Gastrointestinal Product and Services
Table 104. Dr. Falk Pharma GmbH Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 105. Dr. Falk Pharma GmbH Recent Developments/Updates
Table 106. Dr. Falk Pharma GmbH Competitive Strengths & Weaknesses
Table 107. Abbott Basic Information, Manufacturing Base and Competitors
Table 108. Abbott Major Business

+357 96 030922
info@marketpublishers.com

Table 109. Abbott Gastrointestinal Product and Services
Table 110. Abbott Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 111. Abbott Recent Developments/Updates
Table 112. Abbott Competitive Strengths & Weaknesses
Table 113. Jiangzhong Basic Information, Manufacturing Base and Competitors
Table 114. Jiangzhong Major Business
Table 115. Jiangzhong Gastrointestinal Product and Services
Table 116. Jiangzhong Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 117. Jiangzhong Recent Developments/Updates
Table 118. Jiangzhong Competitive Strengths & Weaknesses
Table 119. Xian-Janssen Basic Information, Manufacturing Base and Competitors
Table 120. Xian-Janssen Major Business
Table 121. Xian-Janssen Gastrointestinal Product and Services
Table 122. Xian-Janssen Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 123. Xian-Janssen Recent Developments/Updates
Table 124. Xian-Janssen Competitive Strengths & Weaknesses
Table 125. Takeda Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 126. Takeda Pharmaceutical Major Business
Table 127. Takeda Pharmaceutical Gastrointestinal Product and Services
Table 128. Takeda Pharmaceutical Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 129. Takeda Pharmaceutical Recent Developments/Updates
Table 130. Takeda Pharmaceutical Competitive Strengths & Weaknesses
Table 131. AbbVie Basic Information, Manufacturing Base and Competitors
Table 132. AbbVie Major Business
Table 133. AbbVie Gastrointestinal Product and Services
Table 134. AbbVie Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 135. AbbVie Recent Developments/Updates
Table 136. AbbVie Competitive Strengths & Weaknesses
Table 137. Eli Lilly and Company Basic Information, Manufacturing Base and Competitors
Table 138. Eli Lilly and Company Major Business
Table 139. Eli Lilly and Company Gastrointestinal Product and Services
Table 140. Eli Lilly and Company Gastrointestinal Revenue, Gross Margin and Market

+357 96 030922
info@marketpublishers.com

Share (2021-2026) & (USD Million)
Table 141. Eli Lilly and Company Recent Developments/Updates
Table 142. Eli Lilly and Company Competitive Strengths & Weaknesses
Table 143. Johnson & Johnson Basic Information, Manufacturing Base and Competitors
Table 144. Johnson & Johnson Major Business
Table 145. Johnson & Johnson Gastrointestinal Product and Services
Table 146. Johnson & Johnson Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 147. Johnson & Johnson Recent Developments/Updates
Table 148. Johnson & Johnson Competitive Strengths & Weaknesses
Table 149. Bristol Myers Squibb Basic Information, Manufacturing Base and Competitors
Table 150. Bristol Myers Squibb Major Business
Table 151. Bristol Myers Squibb Gastrointestinal Product and Services
Table 152. Bristol Myers Squibb Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 153. Bristol Myers Squibb Recent Developments/Updates
Table 154. Bristol Myers Squibb Competitive Strengths & Weaknesses
Table 155. Bausch Health Basic Information, Manufacturing Base and Competitors
Table 156. Bausch Health Major Business
Table 157. Bausch Health Gastrointestinal Product and Services
Table 158. Bausch Health Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 159. Bausch Health Recent Developments/Updates
Table 160. Bausch Health Competitive Strengths & Weaknesses
Table 161. Livzon Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 162. Livzon Pharmaceutical Major Business
Table 163. Livzon Pharmaceutical Gastrointestinal Product and Services
Table 164. Livzon Pharmaceutical Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 165. Livzon Pharmaceutical Recent Developments/Updates
Table 166. Livzon Pharmaceutical Competitive Strengths & Weaknesses
Table 167. Shandong Luoxin Pharmaceutical Basic Information, Manufacturing Base and Competitors
Table 168. Shandong Luoxin Pharmaceutical Major Business
Table 169. Shandong Luoxin Pharmaceutical Gastrointestinal Product and Services
Table 170. Shandong Luoxin Pharmaceutical Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)

+357 96 030922
info@marketpublishers.com

Table 171. Shandong Luoxin Pharmaceutical Recent Developments/Updates
Table 172. Shandong Luoxin Pharmaceutical Competitive Strengths & Weaknesses
Table 173. Gilead Sciences Basic Information, Manufacturing Base and Competitors
Table 174. Gilead Sciences Major Business
Table 175. Gilead Sciences Gastrointestinal Product and Services
Table 176. Gilead Sciences Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 177. Gilead Sciences Recent Developments/Updates
Table 178. Gilead Sciences Competitive Strengths & Weaknesses
Table 179. Zhengdatianqing Basic Information, Manufacturing Base and Competitors
Table 180. Zhengdatianqing Major Business
Table 181. Zhengdatianqing Gastrointestinal Product and Services
Table 182. Zhengdatianqing Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 183. Zhengdatianqing Recent Developments/Updates
Table 184. Zhengdatianqing Competitive Strengths & Weaknesses
Table 185. Zydus Lifesciences Basic Information, Manufacturing Base and Competitors
Table 186. Zydus Lifesciences Major Business
Table 187. Zydus Lifesciences Gastrointestinal Product and Services
Table 188. Zydus Lifesciences Gastrointestinal Revenue, Gross Margin and Market Share (2021-2026) & (USD Million)
Table 189. Zydus Lifesciences Recent Developments/Updates
Table 190. Zydus Lifesciences Competitive Strengths & Weaknesses
Table 191. Global Key Players of Gastrointestinal Upstream (Raw Materials)
Table 192. Global Gastrointestinal Typical Customers

+357 96 030922
info@marketpublishers.com

List Of Figures

LIST OF FIGURES

Figure 1. Gastrointestinal Picture
Figure 2. World Gastrointestinal Total Revenue: 2021 & 2025 & 2032, (USD Million)
Figure 3. World Gastrointestinal Total Revenue (2021-2032) & (USD Million)
Figure 4. World Gastrointestinal Revenue by Region (2021, 2025 and 2032) & (USD Million), (by Headquarter Location)
Figure 5. World Gastrointestinal Revenue Market Share by Region (2021-2032), (by Headquarter Location)
Figure 6. United States Based Company Gastrointestinal Revenue (2021-2032) & (USD Million)
Figure 7. China Based Company Gastrointestinal Revenue (2021-2032) & (USD Million)
Figure 8. Europe Based Company Gastrointestinal Revenue (2021-2032) & (USD Million)
Figure 9. Japan Based Company Gastrointestinal Revenue (2021-2032) & (USD Million)
Figure 10. South Korea Based Company Gastrointestinal Revenue (2021-2032) & (USD Million)
Figure 11. ASEAN Based Company Gastrointestinal Revenue (2021-2032) & (USD Million)
Figure 12. India Based Company Gastrointestinal Revenue (2021-2032) & (USD Million)
Figure 13. Gastrointestinal Market Drivers
Figure 14. Factors Affecting Demand
Figure 15. World Gastrointestinal Consumption Value (2021-2032) & (USD Million)
Figure 16. World Gastrointestinal Consumption Value Market Share by Region (2021-2032)
Figure 17. United States Gastrointestinal Consumption Value (2021-2032) & (USD Million)
Figure 18. China Gastrointestinal Consumption Value (2021-2032) & (USD Million)
Figure 19. Europe Gastrointestinal Consumption Value (2021-2032) & (USD Million)
Figure 20. Japan Gastrointestinal Consumption Value (2021-2032) & (USD Million)
Figure 21. South Korea Gastrointestinal Consumption Value (2021-2032) & (USD Million)
Figure 22. ASEAN Gastrointestinal Consumption Value (2021-2032) & (USD Million)
Figure 23. India Gastrointestinal Consumption Value (2021-2032) & (USD Million)
Figure 24. Producer Shipments of Gastrointestinal by Player Revenue ($MM) and Market Share (%): 2025
Figure 25. Global Four-firm Concentration Ratios (CR4) for Gastrointestinal Markets in

+357 96 030922
info@marketpublishers.com

2025
Figure 26. Global Four-firm Concentration Ratios (CR8) for Gastrointestinal Markets in 2025
Figure 27. United States VS China: Gastrointestinal Revenue Market Share Comparison (2021 & 2025 & 2032)
Figure 28. United States VS China: Gastrointestinal Consumption Value Market Share Comparison (2021 & 2025 & 2032)
Figure 29. World Gastrointestinal Market Size by Type, (USD Million), 2021 & 2025 & 2032
Figure 30. World Gastrointestinal Market Size Market Share by Type in 2025
Figure 31. Acid-Related Disorder Drugs
Figure 32. Inflammatory Bowel Disease Drugs
Figure 33. Irritable Bowel Syndrome Drugs
Figure 34. Constipation Drugs
Figure 35. Diarrhea Drugs
Figure 36. Gastrointestinal Motility Disorder Drugs
Figure 37. Other Gastrointestinal Drugs
Figure 38. Other Gastrointestinal Drugs
Figure 39. World Gastrointestinal Market Size Market Share by Type (2021-2032)
Figure 40. World Gastrointestinal Market Size by Primary Dosage Form, (USD Million), 2021 & 2025 & 2032
Figure 41. World Gastrointestinal Market Size Market Share by Primary Dosage Form in 2025
Figure 42. Oral Solid Preparations
Figure 43. Oral Liquid and Suspension Preparations
Figure 44. Injectable Preparations
Figure 45. Rectal Preparations
Figure 46. Other Preparations
Figure 47. World Gastrointestinal Market Size Market Share by Primary Dosage Form (2021-2032)
Figure 48. World Gastrointestinal Market Size by Drug Molecule, (USD Million), 2021 & 2025 & 2032
Figure 49. World Gastrointestinal Market Size Market Share by Drug Molecule in 2025
Figure 50. Small Molecule Drugs
Figure 51. Biologic Drugs
Figure 52. World Gastrointestinal Market Size Market Share by Drug Molecule (2021-2032)
Figure 53. World Gastrointestinal Market Size by Application, (USD Million), 2021 & 2025 & 2032

+357 96 030922
info@marketpublishers.com

Figure 54. World Gastrointestinal Market Size Market Share by Application in 2025
Figure 55. Hospitals
Figure 56. Gastroenterology Clinics
Figure 57. Retail Pharmacies
Figure 58. Online Pharmacies
Figure 59. World Gastrointestinal Market Size Market Share by Application (2021-2032)
Figure 60. Gastrointestinal Industrial Chain
Figure 61. Methodology
Figure 62. Research Process and Data Source

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Global Gastrointestinal Supply, Demand and Key Producers, 2026-2032

Product link: https://marketpublishers.com/r/GE89CA7F3BC9EN.html

Price: US$ 4,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/GE89CA7F3BC9EN.html